Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1996 Jan;64(1):355–357. doi: 10.1128/iai.64.1.355-357.1996

Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR.

D W Acheson 1, M M Levine 1, J B Kaper 1, G T Keusch 1
PMCID: PMC173768  PMID: 8557364

Abstract

This study addresses a mechanism for inducing systemic immunity to Shiga-like toxins by oral administration of a Shiga-like toxin I B-subunit-expressing Vibrio cholerae vaccine strain [CVD 103-HgR(pDA60)]. Two sets of three rabbits were given either CVD 103-HgR or CVD 103-HgR(pDA60) orally. All rabbits immunized with CVD 103-HgR(pDA60) developed neutralizing serum antibodies to Shiga-like toxin I. None of the controls developed such antibodies.

Full Text

The Full Text of this article is available as a PDF (183.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acheson D. W., Calderwood S. B., Boyko S. A., Lincicome L. L., Kane A. V., Donohue-Rolfe A., Keusch G. T. Comparison of Shiga-like toxin I B-subunit expression and localization in Escherichia coli and Vibrio cholerae by using trc or iron-regulated promoter systems. Infect Immun. 1993 Mar;61(3):1098–1104. doi: 10.1128/iai.61.3.1098-1104.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Acheson D. W., De Breucker S. A., Jacewicz M., Lincicome L. L., Donohue-Rolfe A., Kane A. V., Keusch G. T. Expression and purification of Shiga-like toxin II B subunits. Infect Immun. 1995 Jan;63(1):301–308. doi: 10.1128/iai.63.1.301-308.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Endo Y., Tsurugi K., Yutsudo T., Takeda Y., Ogasawara T., Igarashi K. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem. 1988 Jan 15;171(1-2):45–50. doi: 10.1111/j.1432-1033.1988.tb13756.x. [DOI] [PubMed] [Google Scholar]
  4. Gentry M. K., Dalrymple J. M. Quantitative microtiter cytotoxicity assay for Shigella toxin. J Clin Microbiol. 1980 Sep;12(3):361–366. doi: 10.1128/jcm.12.3.361-366.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gordon V. M., Whipp S. C., Moon H. W., O'Brien A. D., Samuel J. E. An enzymatic mutant of Shiga-like toxin II variant is a vaccine candidate for edema disease of swine. Infect Immun. 1992 Feb;60(2):485–490. doi: 10.1128/iai.60.2.485-490.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hofmann S. L. Southwestern Internal Medicine Conference: Shiga-like toxins in hemolytic-uremic syndrome and thrombotic thrombocytopenic purpura. Am J Med Sci. 1993 Dec;306(6):398–406. doi: 10.1097/00000441-199312000-00009. [DOI] [PubMed] [Google Scholar]
  7. Jacewicz M., Clausen H., Nudelman E., Donohue-Rolfe A., Keusch G. T. Pathogenesis of shigella diarrhea. XI. Isolation of a shigella toxin-binding glycolipid from rabbit jejunum and HeLa cells and its identification as globotriaosylceramide. J Exp Med. 1986 Jun 1;163(6):1391–1404. doi: 10.1084/jem.163.6.1391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kandel G., Donohue-Rolfe A., Donowitz M., Keusch G. T. Pathogenesis of Shigella diarrhea. XVI. Selective targetting of Shiga toxin to villus cells of rabbit jejunum explains the effect of the toxin on intestinal electrolyte transport. J Clin Invest. 1989 Nov;84(5):1509–1517. doi: 10.1172/JCI114327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Karmali M. A. Infection by verocytotoxin-producing Escherichia coli. Clin Microbiol Rev. 1989 Jan;2(1):15–38. doi: 10.1128/cmr.2.1.15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Karmali M. A., Petric M., Lim C., Fleming P. C., Arbus G. S., Lior H. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis. 1985 May;151(5):775–782. doi: 10.1093/infdis/151.5.775. [DOI] [PubMed] [Google Scholar]
  11. Keusch G. T., Grady G. F., Mata L. J., McIver J. The pathogenesis of Shigella diarrhea. I. Enterotoxin production by Shigella dysenteriae I. J Clin Invest. 1972 May;51(5):1212–1218. doi: 10.1172/JCI106915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Levine M. M., Kaper J. B., Herrington D., Ketley J., Losonsky G., Tacket C. O., Tall B., Cryz S. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet. 1988 Aug 27;2(8609):467–470. doi: 10.1016/s0140-6736(88)90120-1. [DOI] [PubMed] [Google Scholar]
  13. Morrison D. M., Tyrrell D. L., Jewell L. D. Colonic biopsy in verotoxin-induced hemorrhagic colitis and thrombotic thrombocytopenic purpura (TTP). Am J Clin Pathol. 1986 Jul;86(1):108–112. doi: 10.1093/ajcp/86.1.108. [DOI] [PubMed] [Google Scholar]
  14. Obrig T. G., Del Vecchio P. J., Brown J. E., Moran T. P., Rowland B. M., Judge T. K., Rothman S. W. Direct cytotoxic action of Shiga toxin on human vascular endothelial cells. Infect Immun. 1988 Sep;56(9):2373–2378. doi: 10.1128/iai.56.9.2373-2378.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Stein P. E., Boodhoo A., Tyrrell G. J., Brunton J. L., Read R. J. Crystal structure of the cell-binding B oligomer of verotoxin-1 from E. coli. Nature. 1992 Feb 20;355(6362):748–750. doi: 10.1038/355748a0. [DOI] [PubMed] [Google Scholar]
  16. Steinberg S. E., Banwell J. G., Yardley J. H., Keusch G. T., Hendrix T. R. Comparison of secretory and histological effects of shigella and cholera enterotoxins in rabbit jejunum. Gastroenterology. 1975 Feb;68(2):309–317. [PubMed] [Google Scholar]
  17. Waddell T., Head S., Petric M., Cohen A., Lingwood C. Globotriosyl ceramide is specifically recognized by the Escherichia coli verocytotoxin 2. Biochem Biophys Res Commun. 1988 Apr 29;152(2):674–679. doi: 10.1016/s0006-291x(88)80091-3. [DOI] [PubMed] [Google Scholar]
  18. Wadolkowski E. A., Sung L. M., Burris J. A., Samuel J. E., O'Brien A. D. Acute renal tubular necrosis and death of mice orally infected with Escherichia coli strains that produce Shiga-like toxin type II. Infect Immun. 1990 Dec;58(12):3959–3965. doi: 10.1128/iai.58.12.3959-3965.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. van de Kar N. C., Monnens L. A., Karmali M. A., van Hinsbergh V. W. Tumor necrosis factor and interleukin-1 induce expression of the verocytotoxin receptor globotriaosylceramide on human endothelial cells: implications for the pathogenesis of the hemolytic uremic syndrome. Blood. 1992 Dec 1;80(11):2755–2764. [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES